Consumers Rejected Drug Plan That Mirrors Trump Administration Proposal
What to know about PBMs and rebates ahead of the Senate drug price hearing on — you guessed it — PBMs.
Drugs
821-840 of 1,312 results
-
-
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don’t have to.
-
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don’t have to.
-
Doughnut Hole Is Gone, But Medicare’s Uncapped Drug Costs Still Bite Into Budgets
Beneficiaries pay 25 percent of the price of their brand-name drugs until they reach $5,100 in out-of-pocket costs. After that, their obligation drops to 5 percent. But it never disappears.
-
Analysis: Why Americans Shouldn’t Feel Grateful For $137 Insulin
Only by the bizarre logic of the U.S. pharmaceutical industry does this drug count as any kind of generic.
-
Must-Reads Of The Week (Some Flying Below The Radar)
Executive editor Damon Darlin takes a spin as host of “The Friday Breeze,” whirling through a week of health care news so you don’t have to.
By Damon Darlin -
Podcast: KHN’s ‘What The Health?’ The Karma Of Cutting Medicare
Stephanie Armour of The Wall Street Journal, Alice Ollstein of Politico and Rebecca Adams of CQ Roll Call join KHN’s Julie Rovner to discuss the suggested cuts to health programs in President Donald Trump’s budget proposal, the latest on lawsuits challenging work requirements for Medicaid enrollees and the FDA’s crackdown on e-cigarettes. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week.
-
How Much Difference Will Eli Lilly’s Half-Price Insulin Make?
Eli Lilly released a half-price generic version of its own short-acting insulin. At $137.35 per vial, the generic insulin is priced at about the same level as Humalog was in 2012.
-
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don’t have to.
-
Lawmakers United Against High Drug Prices Bare Partisan Teeth
Clear differences of opinion emerged between Democrats and Republicans during a House Ways and Means subcommittee hearing about how to make prescription drugs more affordable in the Medicare program.
By Rachel Bluth -
Cities And Counties Unlikely To Heed FDA Warning On Importing Foreign Drugs
The Food and Drug Administration claims CanaRX, a company used by more than 500 cities, counties and school districts to help their employees get cheaper drugs from overseas, has sent “unapproved” and “misbranded” drugs to U.S. consumers, jeopardizing their safety.
-
The Promise Of Youth, The Reality Of Aging
Patients Experiment With Prescription Drugs To Fight Aging
Doctors and patients say they’re compelled to use off-label meds as research goes unfunded.
-
Big Pharma Gave Money To Patient Advocacy Groups Opposing Medicare Changes
A KHN database shows that $58 million flowed from drugmakers to patient groups running national ads.
-
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don’t have to.
-
Watch: Big Week For Drug Pricing Debate Featured On C-SPAN
KHN correspondent Emmarie Huetteman appeared on the C-SPAN program “Washington Journal,” where she fielded viewers’ calls about high drug prices and industry criticism.
-
Americans Ready To Crack Down On Drug Prices That Force Some To Skip Doses
In a new poll, consumers give thumbs up to ads that display drug prices and the removal of barriers to generics, among other cost-cutting measures.
By Jay Hancock -
Podcast: KHN’s ‘What The Health?’ ‘Medicare-For-All’ Debate: Who’s Going To Pay
Margot Sanger-Katz of The New York Times, Paige Winfield Cunningham of The Washington Post and Jennifer Haberkorn of the Los Angeles Times join KHN’s Julie Rovner to discuss the new “Medicare-for-all” bill introduced by House Democrats, the grilling of pharmaceutical company CEOs by a Senate committee and new Trump administration rules that take aim at Planned Parenthood. Plus, Rovner interviews KHN’s Julie Appleby about the latest “Bill of the Month” installment.
-
Pharma Execs Dig In For A Fight Against Outraged Senators
The Senate Finance Committee grilled executives from seven major drugmakers on Tuesday.
By Emmarie Huetteman and Jay Hancock -
Congress Squares Off With Pharma CEOs In Showdown Over High Drug Prices
Tuesday’s Senate Finance Committee hearing could produce fireworks over prices, R&D costs and executive compensation.
By Emmarie Huetteman and Jay Hancock -
In Florida, Drug Importation From Canada Finds New Champions, Old Snags
The state’s governor said the plan has the full support of the White House. But the Trump administration was noncommittal about whether allowing states to buy and import cheaper drugs from up north could be the answer to the nation’s drug-pricing problem.
By Shefali Luthra and Phil Galewitz